CTX — Crescita Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$14.71m
- CA$8.50m
- CA$21.12m
Brief: Crescita Signs Exclusive Distribution Agreement With Fillmed
Brief: Crescita - Cash And Cash Equivalents Balance Of $13,005 As At Sept 30
Brief: Crescita Therapeutics QTRLY Revenue Was $4.9 Million
Brief: Crescita Therapeutics Says U.S. FDA Approved Enhanced Formulation Of Pliaglis
Brief: Sundial And Crescita Sign Exclusive Partnership To Develop Cannabis And Hemp Topicals
Brief: Crescita Therapeutics Reports Quarterly Earnings Per Share Of C$0.10
Brief: Knight Announces Early Warning Filing Regarding Disposition Of Shares Of Crescita
Brief: U.S. Patent And Trademark Office Issues Patent Covering An Enhanced Formulation Of Pliaglis®
Brief: Crescita Therapeutics Receives 2nd Installment Of Up-Front Pay Of €1.25 Mln After First Commercial Sale Of Pliaglis By Cantabria In Italy
Brief: Crescita Therapeutics Announces Approval Of Normal Course Issuer Bid
Brief: Crescita Therapeutics Announces Intention To Make Normal Course Issuer Bid
Brief: Crescita Therapeutics Reports 2019 First Quarter Results
Brief: Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-Of-World Rights
Brief: Crescita Therapeutics Inc And Tetra Natural Health Collaborate To Enhance Transdermal Delivery Of Beta-Caryophyllene In Tetra's Dermatology Product Portfolio
Brief: Crescita Therapeutics Inc And Tetra Natural Health Collaborate To Enhance Transdermal Delivery Of Beta-Caryophyllene In Tetra's Dermatology Product Portfolio
Brief: U.S. FDA Approves Removal Of "Not For Home Use" Label Restriction For Pliaglis
Brief: Crescita Therapeutics Reports 2018 Third Quarter Results
Brief: Crescita Therapeutics' Patented Delivery Technologies Demonstrate Enhanced Skin Permeation Of Cannabidiol
Brief: Crescita Therapeutics Q2 Revenue C$2.3 Mln Versus C$4.9 Mln